Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...

In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...

Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...

Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar ...

GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached ...

Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...

Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...

With the help of AI, AstraZeneca’s three-in-one inhaler Breztri has a new furry mascot to help it stand tall over the crowded ...

Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...

About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...